deltatrials
Completed PHASE1 NCT04643249

Drug-drug Interaction Study of KL1333 in Healthy Subjects

A Phase I, Open-label, Fixed-sequence, Crossover, Drug-drug Interaction Study to Investigate the Inhibition Potential of KL1333 on CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 in Healthy Subjects

Sponsor: Abliva AB

Conditions Mitochondrial Disease
Interventions Bupropion Caffeine Dextromethorphan Flurbiprofen KL1333 Midazolam injection Omeprazole Repaglinide
Updated 5 times since 2020 Last updated: Oct 19, 2021 Started: Nov 10, 2020 Primary completion: Dec 17, 2020 Completion: Dec 17, 2020

Listed as NCT04643249, this PHASE1 trial focuses on Mitochondrial Disease and remains completed. Sponsored by Abliva AB, it has been updated 5 times since 2020, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Nov 2021 — Jul 2024 [monthly]

    Completed PHASE1

    Status: Recruiting → Completed

  4. Jan 2021 — Nov 2021 [monthly]

    Recruiting PHASE1

  5. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

    First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Abliva AB
Data source: Abliva AB

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Leeds, United Kingdom